KB-1232

Codrituzumab

45356

Background of Codrituzumab

Glypican-3 (GPC3), the target molecule of codrituzumab, is a member of the proteoglycan family. GPC3 plays a crucial role in regulating cell growth and differentiation and is closely associated with the onset and progression of hepatocellular carcinoma (HCC). Research indicates that GPC3 is significantly overexpressed in HCC, while its expression is either absent or markedly reduced in normal adult tissues. This differential expression pattern suggests that GPC3 possesses notable sensitivity and specificity for diagnosing hepatocellular carcinoma. Consequently, GPC3 is emerging as a promising tumor biomarker and therapeutic target for HCC. Codrituzumab (Cod) is a recombinant humanized monoclonal antibody specifically targeting Glypican-3 (GPC3).

Specifications

Catalog Number	KB-1232
Antibody Name	Codrituzumab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	GPC3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma.